Back to Feed
总结
诺和诺德推出的口服版Wegovy减重药在上市首周表现被认为“开局稳健”，并在疗效与市场竞争上被外界拿来与礼来Zepbound对比。受此进展影响，公司股价一度上涨约8%。公司同时判断，到2030年口服GLP-1减重药有望占据整体减重药市场的三分之一以上，显示其正以口服剂型加速争夺快速扩张的肥胖治疗市场份额。
正文
Novo's Wegovy Pill Looks A Lot Like Zepbound - In One Week Investor's Business Daily Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch CNBC Lubbock Doctor compares weight loss injections to new pills KCBD Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030 Reuters Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly Reuters
发布时间：